Skip to main content

Table 6 Critical appraisal of quantitative studies reporting retention

From: The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review

No

Study

MMAT Section 3a for quantitative non-randomized studies

1

2

3

4

5

Are the participants representative of the target population?

Are measurements appropriate regarding both the outcome and intervention (or exposure)?

Are there complete outcome data?

Are the confounders accounted for in the design and analysis?b

During the study period, is the intervention administered (or exposure occurred) as intended?b

S7

Cunningham et al., 2022 [75]

No

Yes

Yes

No

Yes

S9

Farid et al., 2022 [77]

Yes

No

Can't tell

No

No

S11

Garg et al., 2022 [79]

Yes

Yes

Yes

No

No

S13

Gomes et al., 2022 [81]

Yes

Yes

Yes

Yes

Yes

S15

Hoffman et al., 2022 [83]

No

Yes

Yes

Yes

Yes

S26

Nguyen et al., 2021 [94]

No

Yes

Yes

No

No

S31

Roy et al., 2023 [99]

Yes

Yes

Can't tell

No

No

# meeting quality criteria

4/7

6/7

5/7

2/7

3/7

  1. aThe MMAT (Mixed Methods Appraisal Tool) Qualitative Checklist is designed specifically for mixed methods systematic reviews (Hong et al., 2018). It consists of five sections specific to various study designs, each with five quality criteria. All quantitative studies included in this review, including quantitative components of mixed-methods studies, were appraised under Sect. 3: Quantitative non-randomized studies
  2. bThis review included studies in which the intervention of interest (relaxed restrictions on take-home doses) formed part of a broader intervention (e.g., pandemic-related changes to OAT treatment). To increase the relevancy of the quality assessments, we interpreted questions 4 and 5 relevant to the research question posed in this review